Grupo Globo - Mídia E Conteúdo
Business Specialist
University of California, Berkeley, Haas School of Business Aug 2017 - May 2019
Mba Candidate - Class of 2019
Y-Lectry May 2018 - May 2019
Co-Founder
Axlehire May 2018 - Aug 2018
Mba Intern
Klabin Jan 2016 - May 2017
Consultor De Estratã Gia E Mercado
Education:
University of California, Berkeley, Haas School of Business 2017 - 2019
Master of Business Administration, Masters, Business Administration, Management, Business Administration and Management
Insper Instituto De Ensino E Pesquisa 2013 - 2015
Universidade De São Paulo 2006 - 2010
Bachelors, Bachelor of Science, Mechatronics Engineering, Mechanical Engineering
Skills:
Market Analysis Portuguese Business Strategy Marketing Strategy Business Planning English Competitive Analysis Pricing Strategic Planning Spanish Negotiation Planejamento Empresarial
Interests:
Social Services Economic Empowerment Education Environment Poverty Alleviation Science and Technology Health
Synchromedia Laboratory For Multimedia Communication In Telepresence
Master Degree Student
Hughes Do Brasil Apr 2018 - Apr 2019
Telecommunications Engineer
Univesp Sep 2014 - Apr 2018
Engineer and Contract Manager
Sky Brasil May 2014 - Aug 2014
Core Engineer Specialist
Claro Dec 2012 - Apr 2014
Senior Engineer
Education:
École De Technologie Supérieure 2019 - 2021
Master of Science, Masters
Universidade Paulista 2016 - 2018
Universidade Federal Do Rio De Janeiro 2009 - 2012
Master of Science, Masters
Universidade Estadual Paulista Júlio De Mesquita Filho 2004 - 2008
Bachelors, Bachelor of Science, Electrical Engineering
Universidad De La República 2008 - 2008
Skills:
Telecommunications Lte Linux 3G Mobile Devices Gsm Tcp/Ip Matlab Gprs Engineering Microsoft Office Networking Open Source Software Cisco Technologies Troubleshooting Wireless Teamwork Windows Training Delivery 4G Umts Ip Mobile Communications 2G Technical Training Switches Internet Protocol Wireless Technologies 3Gpp Operating Systems Routers Electrical Engineering Vsat Core Network
e are pleased that the FDA has granted breakthrough therapy designation for our T-cell therapy in synovial sarcoma, recognizing both the unmet need for patients suffering from this disease as well as the promise of these early data, said Rafael Amado, MD, chief medical officer at Adaptimmune. We l
"We are pleased that the FDA has granted breakthrough therapy designation for our T-cell therapy in synovial sarcoma, recognizing both the unmet need for patients suffering from this disease as well as the promise of these early data," said Rafael Amado, Adaptimmune's chief medical officer. "We look
Date: Feb 09, 2016
Category: Health
Source: Google
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptim...
re pleased that the FDA has granted Breakthrough Therapy designation for our T-cell therapy in synovial sarcoma, recognizingboth the unmet need for patientssuffering from this disease as well asthe promise of these early data, saidDr. Rafael Amado, Adaptimmunes Chief Medical Officer.We look
patients during the first four cycles of treatment. Dr. Rafael Amado, Senior Vice President Oncology R&D at GSK, said, "Cytopenias are important complications of MDS which tend to worsen with azacitidine treatment. Currently, there are no approved treatments for MDS that stimulate platelet production.
Date: Jun 30, 2014
Category: Business
Source: Google
GSK and Genmab announce top-line results from a Phase III study of ...
scientific community as soon it became available. We will now work to further analyse the data and to better understand the totality of the efficacy and safety findings," said Dr. Rafael Amado, Head of Oncology R&D at GSK. "We are very grateful to the CLL patients who participated in this trial.
Date: Jun 27, 2014
Category: Health
Source: Google
Glaxo's Arzerra Lukemia Drug Misses Key Target in Clinical Trial
It was our priority to share this result with the scientific community as soon as it became available, said Dr. Rafael Amado, head of oncology R&D at Glaxo. We will now work to further analyze the data and to better understand the totality of the efficacy and safety findings.
Date: Jun 27, 2014
Category: Health
Source: Google
Tykerb, Avastin suffer disappointing data at SABCS
had a slightly improved rate of progression-free survival, the difference when compared with placebo wasn't statistically significant. "Although we are disappointed,"GSK SVP Rafael Amado said, "[Tykerb] remains an important treatment option for patients with metastasis HER2-positive breast cancer."